FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment

Pallavi Madhiraju- October 5, 2024 0

In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb's Opdivo ... Read More

Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL

Pallavi Madhiraju- September 20, 2024 0

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with ... Read More

EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer

Pallavi Madhiraju- July 7, 2024 0

AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a ... Read More

Roche reports setback in lung cancer study with tiragolumab and tecentriq combination

Pallavi Madhiraju- July 7, 2024 0

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More

GSK announces significant survival results for Jemperli in endometrial cancer trial

Pallavi Madhiraju- March 18, 2024 0

In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

Pallavi Madhiraju- January 28, 2024 0

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

Venus Remedies expands cancer drug portfolio in South Eastern Europe

Pallavi Madhiraju- September 21, 2023 0

In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted marketing authorization from Serbia for chemotherapy drugs ... Read More

AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China

Pallavi Madhiraju- July 15, 2023 0

The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More

Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer

Raghuram Kadari- February 10, 2023 0

Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More

Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer

Pallavi Madhiraju- October 16, 2022 0

Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More

1210 / 17 Posts